- Thin, offensive smelling vaginal discharge
- Vaginal odour
Frequently recurs
NB: Not typically associated with itch, soreness or irritation
We asked you in January to update to v4.7.2. After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.
To update to the latest release:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Welcome to the February 2025 update from the RDS team
A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:
The release will also incorporate a number of small fixes, including:
We will let you know when the date and time for the new release are confirmed.
There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.
The Benzodiazepine tapering tool is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.
Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.
At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .
We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.
Some important toolkits in development by the RDS team include:
The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.
To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)
To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form - also available in End-user and Provider sections of the RDS Learning and Support area. If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.
With kind regards
Right Decision Service team
Healthcare Improvement Scotland
What’s New
Tinidazole no longer available
Delaquinium chloride is a licensed 2nd line option
Note IUSTI guideline advice that BV commoner in women with an IUCD
Bacterial Vaginosis is the most common microbiological cause of abnormal vaginal discharge.
It is caused by an overgrowth of anaerobic organisms.
Frequently recurs
NB: Not typically associated with itch, soreness or irritation
Thin, white homogenous discharge coating introitus and vaginal walls, it may look slightly frothy. A characteristic odour is often noted
NB: vulval inflammation is not typical in BV
In genitourinary settings two approaches to the diagnosis of BV are widely used:
Amsel’s criteria and the Hay/Ison criteria 1. Both require microscopy to be available, which is not always the case in sexual health clinics. Where available, microscopy can be used, but syndromic management is supported by national guidelines1,2
The Hay/Ison Criteria (used in the NaSH microscopy page) are:
Grade 0 no bacteria seen
Grade 1 (Normal): Lactobacillus morphotypes predominate
Grade 2 (Intermediate): Mixed flora with some Lactobacilli present, but Gardnerella or Mobiluncus morphotypes also present
Grade 3 (BV): Predominantly Gardnerella and/or Mobiluncus morphotypes. Few or absent Lactobacilli.
Grade 4 Gram positive cocci predominate (consider aerobic vaginitis)
Amsel’s criteria are at least three out of:
(1) Thin, white, homogeneous discharge
(2) Clue cells on microscopy of wet mount
(3) pH of vaginal fluid >4.5
(4) Release of a fishy odour on adding alkali (10% KOH).
History
Diagnosis can be made on the basis of
It is important to take a sexual history to consider the risk of STI and offer STI testing as appropriate as Chlamydia and Gonorrhoea can co-exist. A cervical screening history should be taken as cervical cancer is a differential diagnosis of a smelly discharge. Also consider if a tampon could have been retained.
If possible undertake vulval and speculum examination to visualise any discharge. Inspect the cervix to
exclude any abnormality as a cause of offensive discharge.
Tests options
Not recommended:
High vaginal swabs are of limited value in diagnosing BV as organisms such as gardnerella can be present in 30-40% asymptomatic women. A culture reported as normal does not exclude clinical BV. Microscopy and vaginal pH are far more useful and women reporting recurrent symptoms are better to have a microscopy slide taken.
Asymptomatic women do not need treatment (asymptomatic women should not be being diagnosed as
without symptoms there is no indication to take a test).
General advice
The best ways of preventing BV are not know but avoiding anything that upsets the natural balance of
bacteria in the vagina may help. This includes avoiding:
Use of emollients as a soap substitute for the genital area (available from any pharmacy) is recommended.
BV is more common in women with an IUCD5
If a woman is experiencing recurrent episodes of BV alternative methods can be discussed.
1st line
Metronidazole 400mg oral twice daily 5-7 days (slightly lower relapse rate)
1st line in pregnancy
OR
Metronidazole 2g single oral dose (not recommended in pregnancy)
2nd Line
Clindamycin 300mg oral twice daily 7 days (risk of pseudomembranous colitis)
Or
Dequalinium chloride 10mg vaginal tablets One 10mg vaginal tablet daily for six days6
Insufficient evidence to assess effectiveness but anecdotally useful
Licensed indications
Treatment of BV in adults
Relactagel® : 5 mL( 1 tube) to vagina nightly for 7 nights
Relactagel® is unsuitable for people with an allergy to shellfish as the glycogen is derived from oysters.
There may be a potential risk to a partner who is allergic to shellfish if these have been used.
Balance Activ® is not licenced for treatment
Refer to WOS Pregnancy and STI’s Guideline instead
Non–pregnant women: Not necessary unless symptomatic
Pregnant women: test of cure after a month1
No evidence of benefit in studies of screening and treating male partners
No studies of treatment in female partners although high incidence in female partners of women with BV. If a
female partner is asymptomatic treatment need not be offered routinely.
Consider alternative diagnosis
Check compliance with treatment
Try alternative therapy option - longer course of metronidazole may be more effective than single dose
Sporadic Recurrences
Up to 30% of women have a recurrence within 3 months
Examination and investigation should be considered but may not be necessary if a previous episode of the
signs and symptoms of BV responded to antibiotic treatment, and there are no grounds to suspect an STI or
cervical abnormality.
Frequent Recurrences of Bacterial Vaginosis
This is widely defined as more than four recurrences per year.
Speculum examination should be carried out. The diagnosis should be confirmed with microscopy or HVS.
Negative swabs (or negative dry slide) and persistent symptoms should prompt referral to a sexual health
clinic with microscopy available.
Persistent, symptomatic BV may be associated with the presence of an IUD and an alternative method of
contraception may need to be considered if there is no response to therapy.
Suppressive/preventive treatment
400mg metronidazole oral twice daily for 3 days at start and/or end of menstruation
or
5g 0.75% metronidazole gel intravaginally twice weekly for 16 weeks1
or
Relactagel®: 5 mL (1 tube) nightly to vagina for 2–3 nights after menstruation5
or
Balance Activ RX gel® 5 mL (1 tube) to vagina 1–2 times a week
British National Formulary prices accessed February 2021 NB local contracts may result in
different prices.
Metronidazole 2g | £1.07* |
Metronidazole 400mg b.d. 7 days | £3.50-4.50 |
Metronidazole gel | £4.31 |
Clindamycin 2% Cream | £10.86 |
Clindamycin 300mg b.d. 7 days | £17.84 |
Relactagel 7 x 5ml tubes | £5.25 |
Balance Activ 7 x 5ml tubes | £5.25 |
Delquinium Chloride( Fluomizin) | £6.95 |
Not in BNF : local over labelled pack price 2020
Patient information leaflets
BV information leaflet
https://www.bashhguidelines.org/media/1124/bv_pil_print_2014.pdf (accessed 14/05/2021)
What do you know about...Vaginal health?
http://www.healthscotland.com/documents/3419.aspx
online versions in English, Polish, Chinese, Urdu, Romanian (accessed 14/05/2021)